FOREWORD

Seven extra years of life — what wouldn’t you pay for them? Well, they’re yours. The accelerated pace of medical discovery in the past decade and a half has added those precious seven years to the life expectancy of every American.

Obviously, then, one of the most valuable investments any one of us can make is in medical research — both the basic research which adds to our general fund of knowledge about the human body and the applied research which makes use of that accumulating knowledge for the solution of specific medical problems. Such research has developed cures, or effective treatments, for many of the ills which once plagued mankind. Many others, perhaps the most serious, remain to be conquered. An investment in medical research is not only an investment in health; it is an investment in life itself.

Among the diseases which still baffle physicians is a large group of neuromuscular disorders whose common feature is a kind of creeping paralysis, a slow but progressive destruction of muscle tissue whose end result is death. These tragically disabling disorders, which include that dread crippler of children, muscular dystrophy, afflict people throughout the world. The suffering they cause — to the victims, their families and society in general — is beyond measure. They represent a scientific challenge of such difficulty and magnitude that only in recent years has it begun to be met.
WHAT IS THE INSTITUTE FOR MUSCLE DISEASE?

It is a new research center, the first of its kind in the world, boldly conceived and organized as headquarters for the fight against neuromuscular disease. And since research in this field is, necessarily, of so fundamental a nature, the work done at the Institute will, inevitably, benefit victims of other apparently unrelated conditions. When we consider, for instance, that the heart itself is a giant muscle, we begin to realize the potentialities opened up by concentrated studies in this particular area of medical science.

The Institute is an ultra-modern facility, a scientist’s dream come true. Its laboratories were designed to provide full scope for the most advanced techniques and methodologies currently available. They are so arranged, moreover, that alterations to meet future needs, not now foreseeable, can be made quickly and with a minimum of expense.

These general laboratories occupy five of the building’s eleven floors. Another houses the metabolism unit where twelve research patients will be given the best care and, at the same time, intensively studied under controlled conditions. On still another floor, animal quarters are located; its most interesting inhabitants, scientifically speaking, are a strain of mice with a hereditary myopathy very similar to the childhood form of muscular dystrophy.

Another important feature of the Institute is its immense reference library which, besides containing a complete file of publications dealing with neuromuscular studies, also serves as a center for disseminating information in this field to scientists working in other institutions.
WHY IS SUCH A RESEARCH CENTER NECESSARY?

Research into neuromuscular disorders is of relatively recent origin. While there were a few individual pioneers, there was no large scale effort in this field until after the formation, in 1950, of Muscular Dystrophy Associations of America, Inc. Now one of the nation's leading voluntary health agencies, MDAA currently supports more than 100 separate projects in this country and abroad.

As the Association's program expanded, however, it became clear that its full potential could not be realized under existing circumstances. Among the major impediments were the lack of laboratory space in universities and other research institutions; the exorbitant cost, when used for a single project alone, of the expensive equipment necessary for experiments; and, finally, the difficulty of coordinating work carried on in such widely scattered places.

These considerations motivated MDAA's directors to provide funds for the construction of the Institute for Muscle Disease. In addition to giving investigators the facilities they need, as well as the advantage of working in close collaboration with each other, the Institute will serve as a world clearinghouse, or central bank, for other scientists interested in this broad field.

Some indication of the scope of the Institute's own program may be gained from the profile layout of its facilities shown on this page. The study of muscle and its pathologies involves a number of distinct scientific disciplines and recognized leaders in each have been recruited to head the various divisions. When fully operating, the Institute will have on its scientific staff some 50 post-doctoral investigators and approximately 150 laboratory technicians.
The Institute in relation to the great medical community of which it forms a part.
HOW WILL THE INSTITUTE BE FINANCED?

While the Institute was built with funds provided by MDAA, it was incorporated as a separate entity in June, 1956, and has its own organizational structure, consisting of a Board of Trustees and a Director. They will be responsible for raising the money to support its activities. Preliminary assessment calls for a minimum annual operating budget of $1,500,000.

Some of this money will come from MDAA. For the rest, the Institute’s Trustees must seek help from other organizations, both private and public, and from farsighted individuals.

Every American, indeed every inhabitant of the globe, has a stake in the success of this great new research center.

I.M.D. Board Of Trustees

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ade T. Milhorat, M.D.</td>
<td>Professor of Clinical Medicine</td>
<td>The New York Hospital Cornell Medical Center</td>
</tr>
<tr>
<td>Cornelius P. Rhoads, M.D.</td>
<td>Scientific Director</td>
<td>Sloan-Kettering Institute</td>
</tr>
<tr>
<td></td>
<td>Director of Research</td>
<td>Memorial Center for Cancer and Allied Diseases</td>
</tr>
<tr>
<td>Detlev W. Bronk, Ph.D.</td>
<td>President</td>
<td>Rockefeller Institute for Medical Research</td>
</tr>
<tr>
<td>William Mazer, M.D.</td>
<td>President</td>
<td>Hudson Pulp and Paper Corporation</td>
</tr>
<tr>
<td>Paul Cohen, M.D.</td>
<td>President</td>
<td>Technical Tape Corporation</td>
</tr>
<tr>
<td>Frederick H. Schroeder</td>
<td>Executive Vice President</td>
<td>Lee Higginson Corporation</td>
</tr>
<tr>
<td>Laurence Goodstein</td>
<td>Treasurer</td>
<td>Goodstein Brothers &amp; Company, Inc.</td>
</tr>
<tr>
<td>Felix G. Langer</td>
<td>Attorney at Law</td>
<td></td>
</tr>
<tr>
<td>Frederick N. Goodrich</td>
<td>Vice President</td>
<td>United States Trust Company of New York</td>
</tr>
</tbody>
</table>

Dr. Ade T. Milhorat

Dr. Ade T. Milhorat studied at Columbia and Cornell Universities where he received his A.B. and M.D. degrees respectively. He received his hospital training at Presbyterian Hospital, New York City, and, as a research fellow of the National Research Council, he studied and did research in chemistry for two years in Leipzig, Germany. After his return to this country, he received appointments in the Departments of Medicine and Pharmacology, Cornell University Medical College and New York Hospital, and in the Russell Sage Institute of Pathology. Presently, he is Professor of Clinical Medicine, Cornell University Medical College; Attending Physician, New York Hospital; and Consultant in Neuromuscular Diseases, Hospital for Special Surgery.

During his research in Leipzig, Dr. Milhorat came into close contact with the problem of muscular dystrophy. In 1950, he assisted in the establishment of Muscular Dystrophy Associations of America where he is Chairman of the Medical Advisory Board. He is a member of many medical and scientific societies, a past president of the New York State Board of Medical Examiners, member of the Medical Board of Muscular Dystrophy Association of Canada, honorary member of the French Association for Muscular Dystrophy, and a director of the National Hospital for Speech Disorders and of the U. S. Committee of the International Society for the Welfare of Cripples.
WESTERN UNION
TELEGRAM

P WA597 GOVT NL PD=THE WHITE HOUSE WASHINGTON DC 9=
MRS LOU GEHRI G, NATIONAL CAMPAIGN CHAIRMAN=
MUSCULAR DYSTROPHY ASSOCIATIONS OF AMERICA INC
1790 BROADWAY NYK=

PLEASE GIVE MY GREETINGS TO THOSE ATTENDING THE NATIONAL
CONFERENCE OF CHAPTER REPRESENTATIVES OF MUSCULAR
DYSTROPHY ASSOCIATIONS OF AMERICA.

9 THE NEW INSTITUTE FOR MUSCLE DISEASE WHICH, I
UNDERSTAND, YOU WILL SOON BE DEDICATING, SHOULD
CONTRIBUTE SIGNIFICANTLY TO THE RESEARCH ACCOMPLISHMENTS
OF MODERN MEDICINE. I CONGRATULATE YOU AND WISH YOU
WELL IN YOUR EFFORTS TO RELIEVE SUFFERING AMONG OUR
CITIZENS AFFLICTED WITH MUSCULAR DISEASE=

DWIGHT D EISENHOWER=